Quince Therapeutics
QNCX
100 hedge funds and large institutions have $982M invested in Quince Therapeutics in 2021 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 37 increasing their positions, 17 reducing their positions, and 12 closing their positions.
118% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 17
117% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 12
74% more call options, than puts
Call options by funds: $39.6M | Put options by funds: $22.8M
46% more capital invested
Capital invested by funds: $673M → $982M (+$309M)
16% more funds holding
Funds holding: 86 → 100 (+14)
0% less ownership
Funds ownership: 0.32% → 0.31% (-0%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$11.5M |
| 2 |
ECG
EPIQ Capital Group
San Francisco,
California
|
+$4.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.5M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$2.34M |
| 5 |
JG
Jefferies Group
New York
|
+$2.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SUT
SC US (TTGP)
Menlo Park,
California
|
-$20.1M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$12.2M |
| 3 |
State Street
Boston,
Massachusetts
|
-$4.32M |
| 4 |
BlackRock
New York
|
-$3.27M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.38M |
QNCX Hedge Fund Activity: Q2 2021 in Review
100 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q2 2021, worth a combined $982M — up 46% from $673M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new QNCX positions and 12 closed out — a net gain of 14 holders — while 37 added to existing stakes and 17 trimmed.
The largest buyer was Capital International Investors, adding an estimated $11.5M. The largest seller was SC US (TTGP), cutting an estimated $20.1M.
- 100 institutional investors held Quince Therapeutics (QNCX) as of Q2 2021, up from 86 in Q1 2021.
- Funds reported $982M of Quince Therapeutics stock for Q2 2021, up 46% quarter-over-quarter.
- 26 funds opened new Quince Therapeutics positions in Q2 2021 and 12 closed out, a net change of +14 holders.
- The largest Quince Therapeutics buyer in Q2 2021 was Capital International Investors, an estimated $11.5M added.
- The largest Quince Therapeutics seller in Q2 2021 was SC US (TTGP), an estimated $20.1M sold.
Based on aggregated 13F filings for Q2 2021.